AlphaGo builder's new London lab bets LLMs can't be trusted to reason
Thore Graepel, who helped build DeepMind's AlphaGo, is applying game-winning search techniques to general reasoning. His warning: LLMs can't be trusted to reason.

Loading the region desk
Gathering coverage from this region…
Executive intelligence curated from Europe sources and global coverage.
122 briefings briefings in Europe
Thore Graepel, who helped build DeepMind's AlphaGo, is applying game-winning search techniques to general reasoning. His warning: LLMs can't be trusted to reason.
The Hunger Games and John Wick owner is now in play, with activist pressure mounting and a $3.6 billion market cap on the table.
AI meeting notetaker lands $320M to chase enterprise deals and global expansion.
A thousand researchers are publicly refusing AI tools, and the reason is a warning for every company betting on AI-generated answers.
The UK's top spy says AI is making biological attacks more accessible; Johns Hopkins' Tom Inglesby explains why governments are scrambling and what safeguards could stop it.
Revolut, Halifax, and Emma went dark Tuesday as Google's London cloud region failed. Here's what it means for fintech's reliance on Big Tech infrastructure.
A single-zone failure at Google's London data center disrupted court hearings and left millions unable to pay or move money, exposing the fragility of cloud concentration.
Beijing's EV giants are shifting from exports to local assembly, spending billions to keep their European sales boom alive.
Google's premium ChromeOS-Android hybrid starts at $899, but the first major review says the software can't match the hardware. A risky debut against the MacBook Air and Surface Laptop.
A growing cohort of singles says in-person dating events offer better value than apps, signaling a shift in how people meet.
A Russian military spacecraft closed from hundreds of kilometers to extreme proximity with a commercial satellite, signaling a new orbital threat to private assets.
The all-cash deal adds divesiran, a late-stage-ready rare-disease therapy, to Merck KGaA's pipeline and signals a new wave of RNA therapeutics M&A.